Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
1.
J Virol ; 95(14): e0012321, 2021 06 24.
Article in English | MEDLINE | ID: mdl-33952643

ABSTRACT

African swine fever virus (ASFV) causes a virulent, deadly infection in wild and domestic swine and is currently causing a pandemic covering a contiguous geographical area from Central and Eastern Europe to Asia. No commercial vaccines are available to prevent African swine fever (ASF), resulting in devastating economic losses to the swine industry. The most advanced vaccine candidates are live attenuated strains developed using a genetically modified virulent parental virus. Recently, we developed a vaccine candidate, ASFV-G-ΔI177L, by deleting the I177L gene from the genome of the highly virulent ASFV pandemic strain Georgia (ASFV-G). ASFV-G-ΔI177L is safe and highly efficacious in challenge studies using parental ASFV-G. Large-scale production of ASFV-G-ΔI177L has been limited because it can replicate efficiently only in primary swine macrophages. Here, we present the development of an ASFV-G-ΔI177L derivative strain, ASFV-G-ΔI177L/ΔLVR, that replicates efficiently in a stable porcine cell line. In challenge studies, ASFV-G-ΔI177L/ΔLVR maintained the same level of attenuation, immunogenic characteristics, and protective efficacy as ASFV-G-ΔI177L. ASFV-G-ΔI177L/ΔLVR is the first rationally designed ASF vaccine candidate that can be used for large-scale commercial vaccine manufacture. IMPORTANCE African swine fever is currently causing a pandemic resulting in devastating losses to the swine industry. Experimental ASF vaccines rely on the production of vaccine in primary swine macrophages, which are difficult to use for the production of a vaccine on a commercial level. Here, we report a vaccine for ASFV with a deletion in the left variable region (LVR). This deletion allows for growth in stable cell cultures while maintaining the potency and efficacy of the parental vaccine strain. This discovery will allow for the production of an ASF vaccine on a commercial scale.


Subject(s)
African Swine Fever Virus/immunology , African Swine Fever/prevention & control , Viral Vaccines/immunology , African Swine Fever/immunology , African Swine Fever Virus/genetics , Animals , Cell Culture Techniques , Cell Line , Immunogenicity, Vaccine , Macrophages/virology , Pandemics , Sequence Deletion , Swine , Vaccines, Attenuated/genetics , Vaccines, Attenuated/immunology , Viral Vaccines/genetics , Virus Cultivation/methods , Virus Replication
2.
J Virol ; 95(12)2021 05 24.
Article in English | MEDLINE | ID: mdl-33827941

ABSTRACT

The classical swine fever virus (CSFV) glycoprotein E2 is the major structural component of the virus particle. E2 is involved in several functions, such as virus adsorption to the cell, the elicitation of protective immune responses, and virus virulence in swine. Using a yeast two-hybrid system, we previously identified the swine host protein Torsin-1A, an ATPase protein residing in the endoplasmic reticulum and inner nucleus membrane of the cell, as a specific binding partner for E2. The interaction between Torsin-1A and E2 proteins was confirmed to occur in CSFV-infected swine cells using three independent methods: coimmunoprecipitation, confocal microscopy, and proximity ligation assay (PLA). Furthermore, the E2 residue critical to mediate the protein-protein interaction with Torsin-1A was identified by a reverse yeast two-hybrid assay using a randomly mutated E2 library. A recombinant CSFV E2 mutant protein with a Q316L substitution failed to bind swine Torsin-1A in the yeast two-hybrid model. In addition, a CSFV infectious clone harboring the E2 Q316L substitution, although expressing substantial levels of E2 protein, repetitively failed to produce virus progeny when the corresponding RNA was transfected into susceptible SK6 cells. Importantly, PLA analysis of the transfected cells demonstrated an abolishment of the interaction between E2 Q316L and Torsin-1A, indicating a critical role for that interaction during CSFV replication.IMPORTANCE Structural glycoprotein E2 is an important structural component of the CSFV particle. E2 is involved in several virus functions, particularly virus-host interactions. Here, we characterized the interaction between CSFV E2 and swine protein Torsin-1A during virus infection. The critical amino acid residue in E2 mediating the interaction with Torsin-1A was identified and the effect of disrupting the E2-Torsin-1A protein-protein interaction was studied using reverse genetics. It is shown that the amino acid substitution abrogating E2-Torsin-1A interaction constitutes a lethal mutation, demonstrating that this virus-host protein-protein interaction is a critical factor during CSFV replication. This highlights the potential importance of the E2-Torsin-1A protein-protein interaction during CSFV replication and provides a potential pathway toward blocking virus replication, an important step toward the potential development of novel virus countermeasures.


Subject(s)
Classical Swine Fever Virus/physiology , Molecular Chaperones/metabolism , Viral Envelope Proteins/metabolism , Amino Acid Substitution , Animals , Cell Line , Classical Swine Fever Virus/metabolism , Host-Pathogen Interactions , Molecular Chaperones/genetics , Mutation , Protein Binding , Recombinant Proteins/metabolism , Swine , Two-Hybrid System Techniques , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/genetics , Virus Replication
3.
J Virol ; 94(1)2019 12 12.
Article in English | MEDLINE | ID: mdl-31597779

ABSTRACT

The E2 protein in classical swine fever (CSF) virus (CSFV) is the major virus structural glycoprotein and is an essential component of the viral particle. E2 has been shown to be involved in several functions, including virus adsorption, induction of protective immunity, and virulence in swine. Using the yeast two-hybrid system, we previously identified a swine host protein, dynactin subunit 6 (DCTN6) (a component of the cell dynactin complex), as a specific binding partner for E2. We confirmed the interaction between DCTN6 and E2 proteins in CSFV-infected swine cells by using two additional independent methodologies, i.e., coimmunoprecipitation and proximity ligation assays. E2 residues critical for mediating the protein-protein interaction with DCTN6 were mapped by a reverse yeast two-hybrid approach using a randomly mutated E2 library. A recombinant CSFV mutant, E2ΔDCTN6v, harboring specific substitutions in those critical residues was developed to assess the importance of the E2-DCTN6 protein-protein interaction for virus replication and virulence in swine. CSFV E2ΔDCTN6v showed reduced replication, compared with the parental virus, in an established swine cell line (SK6) and in primary swine macrophage cultures. Remarkably, animals infected with CSFV E2ΔDCTN6v remained clinically normal during the 21-day observation period, which suggests that the ability of CSFV E2 to bind host DCTN6 protein efficiently during infection may play a role in viral virulence.IMPORTANCE Structural glycoprotein E2 is an important component of CSFV due to its involvement in many virus activities, particularly virus-host interactions. Here, we present the description and characterization of the protein-protein interaction between E2 and the swine host protein DCTN6 during virus infection. The E2 amino acid residues mediating the interaction with DCTN6 were also identified. A recombinant CSFV harboring mutations disrupting the E2-DCTN6 interaction was created. The effect of disrupting the E2-DCTN6 protein-protein interaction was studied using reverse genetics. It was shown that the same amino acid substitutions that abrogated the E2-DCTN6 interaction in vitro constituted a critical factor in viral virulence in the natural host, domestic swine. This highlights the potential importance of the E2-DCTN6 protein-protein interaction in CSFV virulence and provides possible mechanisms of virus attenuation for the development of improved CSF vaccines.


Subject(s)
Classical Swine Fever Virus/genetics , Classical Swine Fever/virology , Dynactin Complex/genetics , Gene Expression Regulation , Host-Pathogen Interactions/genetics , Viral Envelope Proteins/genetics , Animals , Binding Sites , Cell Line , Classical Swine Fever/mortality , Classical Swine Fever/pathology , Classical Swine Fever Virus/metabolism , Classical Swine Fever Virus/pathogenicity , Dynactin Complex/metabolism , Epithelial Cells/metabolism , Epithelial Cells/virology , Gene Library , Macrophages/metabolism , Macrophages/virology , Mutation , Primary Cell Culture , Protein Binding , Signal Transduction , Survival Analysis , Swine , Two-Hybrid System Techniques , Viral Envelope Proteins/metabolism , Virus Replication
4.
Biotech Histochem ; 93(6): 411-423, 2018.
Article in English | MEDLINE | ID: mdl-29863904

ABSTRACT

Tumor infiltrating lymphocytes (TIL), especially T-cells, have both prognostic and therapeutic applications. The presence of CD8+ effector T-cells and the ratio of CD8+ cells to FOXP3+ regulatory T-cells have been used as biomarkers of disease prognosis to predict response to various immunotherapies. Blocking the interaction between inhibitory receptors on T-cells and their ligands with therapeutic antibodies including atezolizumab, nivolumab, pembrolizumab and tremelimumab increases the immune response against cancer cells and has shown significant improvement in clinical benefits and survival in several different tumor types. The improved clinical outcome is presumed to be associated with a higher tumor infiltration; therefore, it is thought that more accurate methods for measuring the amount of TIL could assist prognosis and predict treatment response. We have developed and validated quantitative immunohistochemistry (IHC) assays for CD3, CD8 and FOXP3 for immunophenotyping T-lymphocytes in tumor tissue. Various types of formalin fixed, paraffin embedded (FFPE) tumor tissues were immunolabeled with anti-CD3, anti-CD8 and anti-FOXP3 antibodies using an IHC autostainer. The tumor area of stained tissues, including the invasive margin of the tumor, was scored by a pathologist (visual scoring) and by computer-based quantitative image analysis. Two image analysis scores were obtained for the staining of each biomarker: the percent positive cells in the tumor area and positive cells/mm2 tumor area. Comparison of visual vs. image analysis scoring methods using regression analysis showed high correlation and indicated that quantitative image analysis can be used to score the number of positive cells in IHC stained slides. To demonstrate that the IHC assays produce consistent results in normal daily testing, we evaluated the specificity, sensitivity and reproducibility of the IHC assays using both visual and image analysis scoring methods. We found that CD3, CD8 and FOXP3 IHC assays met the fit-for-purpose analytical acceptance validation criteria and that they can be used to support clinical studies.


Subject(s)
Biomarkers, Tumor/analysis , Immunohistochemistry , Immunophenotyping , Lymphocytes, Tumor-Infiltrating/metabolism , T-Lymphocytes/immunology , Humans , Immunohistochemistry/methods , Lymphocytes, Tumor-Infiltrating/pathology , Neoplasms/diagnosis , Neoplasms/pathology , Reproducibility of Results
5.
BMC Public Health ; 16: 681, 2016 08 02.
Article in English | MEDLINE | ID: mdl-27484009

ABSTRACT

BACKGROUND: Extensive geographic variation in adverse health outcomes exists, but global measures ignore differences between adjacent geographic areas, which often have very different mortality rates. We describe a novel application of advanced spatial analysis to 1) examine the extent of differences in mortality rates between adjacent counties, 2) describe differences in risk factors between adjacent counties, and 3) determine if differences in risk factors account for the differences in mortality rates between adjacent counties. METHODS: We conducted a cross-sectional study in Missouri, USA with 2005-2009 age-adjusted all-cause mortality rate as the outcome and county-level explanatory variables from a 2007 population-based survey. We used a multi-level Gaussian model and a full Bayesian approach to analyze the difference in risk factors relative to the difference in mortality rates between adjacent counties. RESULTS: The average mean difference in the age-adjusted mortality rate between any two adjacent counties was -3.27 (standard deviation = 95.5) per 100,000 population (maximum = 258.80). Six variables were associated with mortality differences: inability to obtain medical care because of cost (ß = 2.6), hospital discharge rate (ß = 1.03), prevalence of fair/poor health (ß = 2.93), and hypertension (ß = 4.75) and poverty prevalence (ß = 6.08). CONCLUSIONS: Examining differences in mortality rates and associated risk factors between adjacent counties provides additional insight for future interventions to reduce geographic disparities.


Subject(s)
Cause of Death , Health Services Accessibility/statistics & numerical data , Health Status Disparities , Hypertension/mortality , Patient Discharge , Poverty/statistics & numerical data , Bayes Theorem , Costs and Cost Analysis , Cross-Sectional Studies , Female , Humans , Male , Missouri/epidemiology , Patient Discharge/statistics & numerical data , Prevalence , Risk Factors , Spatial Analysis
6.
Ann Surg Oncol ; 21(8): 2659-66, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24748161

ABSTRACT

BACKGROUND: The purpose of this study was to describe hospital and geographic variation in 30-day risk of surgical complications and death among colorectal cancer (CRC) patients and the extent to which patient-, hospital-, and census-tract-level characteristics increased risk of these outcomes. METHODS: We included patients at least 66 years old with first primary stage I-III CRC from the 2000-2005 National Cancer Institute's Surveillance, Epidemiology, and End Results data linked with 1999-2005 Medicare claims. A multilevel, cross-classified logistic model was used to account for nesting of patients within hospitals and within residential census tracts. Outcomes were risk of complications and death after a complication within 30 days of surgery. RESULTS: Data were analyzed for 35,946 patients undergoing surgery at 1,222 hospitals and residing in 12,187 census tracts; 27.2 % of patients developed complications, and of these 13.4 % died. Risk-adjusted variability in complications across hospitals and census tracts was similar. Variability in mortality was larger than variability in complications, across hospitals and across census tracts. Specific characteristics increased risk of complications (e.g., census-tract-poverty rate, emergency surgery, and being African-American). No hospital characteristics increased complication risk. Specific characteristics increased risk of death (e.g. census-tract-poverty rate, being diagnosed with colon (versus rectal) cancer, and emergency surgery), while hospitals with at least 500 beds showed reduced death risk. CONCLUSIONS: Large, unexplained variations exist in mortality after surgical complications in CRC across hospitals and geographic areas. The potential exists for quality improvement efforts targeted at the hospital and/or census-tract levels to prevent complications and augment hospitals' ability to reduce mortality risk.


Subject(s)
Adenocarcinoma, Mucinous/mortality , Colorectal Neoplasms/mortality , Colorectal Surgery/mortality , Hospital Mortality/trends , Postoperative Complications/mortality , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Mucinous/surgery , Aged , Aged, 80 and over , Cause of Death , Colorectal Neoplasms/pathology , Colorectal Neoplasms/surgery , Female , Follow-Up Studies , Geography , Humans , Male , Neoplasm Staging , Prognosis , Retrospective Studies , Risk Factors , Survival Rate
7.
BJOG ; 120(4): 428-34, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23210536

ABSTRACT

OBJECTIVE: To assess rates of neonaticide after the implementation of a preventative 'anonymous delivery' law in mid-2001 in Austria. Women are allowed to access antenatal care and give birth in a hospital anonymously, without showing any ID and free of charge. DESIGN: Retrospective study. SETTING: A complete census of police-reported neonaticides was obtained from the police statistics of Austria, Sweden and Finland. POPULATION: All neonaticides reported to the police, 1991-2009. MAIN OUTCOME MEASURES: Neonaticide rates before (1991-2001) and after (2002-2009) the introduction of anonymous delivery legislation per 100 000 births. METHODS: The Mann-Whitney U-test for two independent samples was used to compare neonaticide rates in the period before the new law was introduced with the rates observed after the implementation of the new law for each country. RESULTS: On average the rate of police-reported neonaticides was 7.2 per 100 000 births (SD 3.5, median 7.1) in Austria prior to the new law being passed, and 3.1 per 100 000 births (SD 2.1, median 2.6) after the law was passed. A significant decrease in neonaticide was observed in Austria after the implementation of anonymous delivery (Mann-Whitney U-test P = 0.017). Whereas the Finnish and Swedish rates were lower than the Austrian rates before and after the implementation of the Austrian law, they remained unchanged over the study period. CONCLUSIONS: Our data demonstrate a significant decrease in the number of police-reported neonaticides in Austria after the implementation of anonymous delivery. Even though underlying factors associated with neonaticide are complex, the findings could indicate an effect of anonymous delivery in the prevention of this crime.


Subject(s)
Confidentiality/legislation & jurisprudence , Delivery, Obstetric/legislation & jurisprudence , Infanticide/prevention & control , Austria/epidemiology , Delivery, Obstetric/methods , Female , Finland/epidemiology , Humans , Infant, Newborn , Infanticide/legislation & jurisprudence , Infanticide/statistics & numerical data , Pregnancy , Prenatal Care/legislation & jurisprudence , Retrospective Studies , Sweden/epidemiology
8.
Oncogene ; 31(36): 4034-44, 2012 Sep 06.
Article in English | MEDLINE | ID: mdl-22158038

ABSTRACT

Mini-chromosome maintenance (Mcm) proteins are part of the replication-licensing complex that is loaded onto chromatin during the G1-phase of the cell cycle and required for initiation of DNA replication in the subsequent S-phase. Mcm proteins are typically loaded in excess of the number of locations that are used during S-phase. Nonetheless, partial depletion of Mcm proteins leads to cancers and stem cell deficiencies. Mcm2 deficient mice, on a 129Sv genetic background, display a high rate of thymic lymphoblastic lymphoma. Here array comparative genomic hybridization is used to characterize the genetic damage accruing in these tumors. The predominant events are deletions averaging less than 0.5 Mbp, considerably shorter than observed in prior studies using alternative mouse lymphoma models or human tumors. Such deletions facilitate identification of specific genes and pathways responsible for the tumors. Mutations in many genes that have been implicated in human lymphomas are recapitulated in this mouse model. These features, and the fact that the mutation underlying the accelerated genetic damage does not target a specific gene or pathway a priori, are valuable features of this mouse model for identification of tumor suppressor genes. Genes affected in all tumors include Pten, Tcfe2a, Mbd3 and Setd1b. Notch1 and additional genes are affected in subsets of tumors. The high frequency of relatively short deletions is consistent with elevated recombination between nearby stalled replication forks in Mcm2-deficient mice.


Subject(s)
Cell Cycle Proteins/deficiency , Genes, Neoplasm , Nuclear Proteins/deficiency , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics , Sequence Deletion , Thymus Neoplasms/genetics , Animals , Base Sequence , Cell Cycle Proteins/genetics , Chromosome Breakpoints , Chromosomes, Mammalian/genetics , Comparative Genomic Hybridization , DNA Copy Number Variations , Humans , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Minichromosome Maintenance Complex Component 2 , Molecular Sequence Data , Nuclear Proteins/genetics , Sequence Analysis, DNA
9.
Oncogene ; 29(25): 3630-8, 2010 Jun 24.
Article in English | MEDLINE | ID: mdl-20440269

ABSTRACT

Minichromosome maintenance proteins (Mcm's) are components of the DNA replication licensing complex. In vivo, reduced expression or activity of Mcm's has been shown to result in highly penetrant early onset cancers (Shima et al., 2007; Pruitt et al., 2007) and stem cell deficiencies (Pruitt et al., 2007). Here we use mouse embryonic fibroblasts from an Mcm2-deficient strain of mice to show by DNA fiber analysis that origin usage is decreased in Mcm2-deficient cells under conditions of hydroxyurea (HU)-mediated replication stress. DNA damage responses (DDRs) resulting from HU and additional replication-dependent and replication-independent genotoxic agents were also examined and shown to function at wild-type (wt) levels. Further, basal levels of many components of the DDR were expressed at wt levels, showing that there is no acute replicative stress under normal growth conditions. Only very modest, 1.5- to 2-fold increases in the basal levels of gamma-H2AX, p21(cip1) and 53bp foci were found, consistent with a slight chronic elevation in DDR pathways. The one condition in which a larger difference between wt- and Mcm2-deficient cells was found occurred after ultraviolet irradiation and may reflect the role of Chk1-mediated suppression of dormant origins. In vivo, abrogating p53-mediated DDR in Mcm2-deficient mice results in increased embryonic lethality and accelerated cancer formation in surviving mice. Further, p53 mutation rescues the negative effect of Mcm2 deficiency on the survival of neural stem cells in vitro; however, the enhanced survival correlates with increased genetic damage relative to Mcm2 wt cells carrying the p53 mutation. Together these results show that even relatively minor perturbations to primary or dormant replication origin usage contribute to accelerated genetic damage in vivo. In addition, these studies show that tumor types resulting from Mcm2 deficiency are strongly affected by interaction with both genetic background and p53.


Subject(s)
Cell Transformation, Neoplastic , DNA Damage , Neoplasms/metabolism , Neoplasms/pathology , Nuclear Proteins/deficiency , Nuclear Proteins/genetics , Alleles , Animals , Cell Line , Cell Proliferation , DNA/chemistry , DNA/genetics , Gene Deletion , Gene Expression Regulation , Humans , Hybridization, Genetic , Mice , Minichromosome Maintenance Complex Component 2 , Neoplasms/genetics , Nervous System/cytology , Stem Cells/cytology , Stem Cells/metabolism , Tumor Suppressor Protein p53/genetics
10.
Cancer Gene Ther ; 16(12): 900-11, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19498460

ABSTRACT

A number of monoclonal antibodies (mAbs) have been studied for their ability to enhance immune responses. Although these antibodies are effective in pre-clinical and clinical studies, they are costly and have occasionally been associated with adverse effects such as autoimmunity and cytokine storm. Numerous studies have shown that treatment of mice with an agonistic mAb, clone DTA-1, targeting murine glucocorticoid-induced tumor necrosis factor receptor (GITR) results in enhanced immune responses in tumor-bearing animals. Herein, we evaluate the novel approach of transfecting dendritic cell (DC) with mRNA encoding the heavy and light chain of the anti-GITR mAb. We show the induction of significantly enhanced tumor immunity by vaccinating with a combination of anti-GITR-secreting DC and tumor antigen-presenting DC. This enhancement is comparable to that seen with systemically delivered mAb along with the antigen-presenting DC. Importantly, when anti-GITR was delivered using RNA-transfected DC, we observed no evidence of autoimmune hypopigmentation in any tumor-free mice. We also show enhanced induction of cytotoxic T-lymphocyte responses, which is only observed when the antigen-presenting and antibody-secreting DC are co-injected at the same site. To illustrate the broad utility of this strategy, we show that DC transfected with mRNA encoding GITR-ligand/Fc fusion protein is also an effective tumor vaccine adjuvant.


Subject(s)
Antibodies, Monoclonal/immunology , Cancer Vaccines/immunology , Dendritic Cells/immunology , Immunotherapy, Adoptive/methods , Melanoma, Experimental/immunology , Melanoma, Experimental/therapy , Receptors, Nerve Growth Factor/immunology , Receptors, Tumor Necrosis Factor/immunology , Animals , Antibodies, Monoclonal/genetics , Antigen Presentation , CHO Cells , Cancer Vaccines/administration & dosage , Cancer Vaccines/genetics , Cell Line, Tumor , Cricetinae , Cricetulus , Dendritic Cells/metabolism , Glucocorticoid-Induced TNFR-Related Protein , Immunoglobulin Fragments/genetics , Immunoglobulin Fragments/immunology , Immunoglobulin Light Chains/genetics , Immunoglobulin Light Chains/immunology , Mice , Mice, Inbred C57BL , RNA/administration & dosage , RNA/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Transfection
11.
Qual Saf Health Care ; 13(4): 299-305, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15289634

ABSTRACT

Chronic conditions are increasingly the primary concern of health care systems throughout the world. In response to this challenge, the World Health Organization has joined with the MacColl Institute for Healthcare Innovation to adapt the Chronic Care Model (CCM) from a global perspective. The resultant effort is the Innovative Care for Chronic Conditions (ICCC) framework which expands community and policy aspects of improving health care for chronic conditions and includes components at the micro (patient and family), meso (health care organisation and community), and macro (policy) levels. The framework provides a flexible but comprehensive base on which to build or redesign health systems in accordance with local resources and demands.


Subject(s)
Chronic Disease/therapy , Community Health Planning/organization & administration , Disease Management , Models, Organizational , Quality Assurance, Health Care/organization & administration , Chronic Disease/epidemiology , Decision Support Systems, Clinical , Delivery of Health Care, Integrated , Global Health , Health Policy , Humans , Leadership , Public Health Practice , Self Care
14.
J Biol Chem ; 276(35): 32489-94, 2001 Aug 31.
Article in English | MEDLINE | ID: mdl-11432851

ABSTRACT

Expression from the mouse Ren-1(c) gene in As4.1 cells is dependent on a proximal promoter element (PPE) located at approximately -60 and a 241-base pair enhancer region located at -2625 relative to the transcription start site. The PPE (TAATAAATCAA) is identical to a consensus HOX.PBX binding sequence. Further, PBX1b has been shown to be a component of a PPE-specific binding complex present in nuclear extracts from As4.1 cells. The binding affinities of different paralog HOX members to the PPE were examined in the absence or presence of PBX1b. HOXB6, -B7, and -C8 failed to bind the PPE alone but showed weak affinity in the presence of PBX1b. In contrast, HOXD10 and to a lesser degree HOXB9 bound the PPE with high affinities regardless of whether PBX1b was present. Abd-B HOX members, including HOXD10, -A10, -A9, -B9, and -C9, are expressed in As4.1 cells. The ability of HOX and PBX1b to form a ternary complex with PREP1 on the PPE is also demonstrated both in vivo and in vitro. Point mutations in either the HOX or PBX half-site of the PPE disrupted the formation of the HOX.PBX complex and dramatically decreased transcriptional activity of the Ren-1(c) gene demonstrating that both the HOX and PBX half-sites are critical for mouse renin gene expression. These results strongly implicate Abd-B class Hox genes and their cofactors as major determinants of the sites of renin expression.


Subject(s)
DNA-Binding Proteins/metabolism , Gene Expression Regulation, Enzymologic , Homeodomain Proteins/metabolism , Promoter Regions, Genetic , Proto-Oncogene Proteins/metabolism , Renin/genetics , Animals , Base Sequence , Binding Sites , Cell Line , Cell Nucleus/metabolism , Consensus Sequence , Humans , Mice , Molecular Sequence Data , Pre-B-Cell Leukemia Transcription Factor 1 , Rats , Reverse Transcriptase Polymerase Chain Reaction , Sequence Alignment , Sequence Homology, Nucleic Acid
16.
J Immunol ; 166(5): 2953-60, 2001 Mar 01.
Article in English | MEDLINE | ID: mdl-11207244

ABSTRACT

Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may represent a superior therapeutic strategy for cancer patients than vaccines solely directed against single Ags. In this study, we show that autologous dendritic cells (DC) transfected with RNA amplified from microdissected tumor cells are capable of stimulating CTL against a broad set of unidentified and critical prostate-specific Ags. Although the polyclonal CTL responses generated with amplified tumor RNA-transfected DC encompassed as a subcomponent a response against prostate-specific Ag (PSA) as well as against telomerase reverse transcriptase, the tumor-specific CTL were consistently more effective than PSA or telomerase reverse transcriptase CTL to lyse tumor targets, suggesting the superiority of the polyclonal response. Although tumor RNA-transfected DC stimulated CTL, which recognized not only tumor but also self-Ags expressed by benign prostate tissue, these cross-reactive CTL were exclusively specific for the PSA, indicating an immunodominant role of PSA in the prostate cancer-specific immune response. Our data suggest that tumor RNA-transfected DC may represent a broadly applicable, potentially clinically effective vaccine strategy for prostate cancer patients, which is not limited by tumor tissue availability for Ag preparation and may minimize the risk of clonal tumor escape.


Subject(s)
Cytotoxicity, Immunologic/genetics , Dendritic Cells/immunology , Epitopes, T-Lymphocyte/immunology , Lymphocyte Activation/genetics , Prostatic Neoplasms/immunology , RNA, Neoplasm/immunology , T-Lymphocytes, Cytotoxic/immunology , Transfection , Adjuvants, Immunologic/genetics , Adjuvants, Immunologic/metabolism , Cells, Cultured , Clone Cells , Cross Reactions/genetics , Cytotoxicity Tests, Immunologic , Dendritic Cells/metabolism , Dissection , Gene Amplification/immunology , Humans , Male , Prostate-Specific Antigen/immunology , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , RNA, Messenger/immunology , RNA, Messenger/metabolism , RNA, Neoplasm/genetics , T-Lymphocytes, Cytotoxic/metabolism , Transcription, Genetic/immunology
17.
Physiol Genomics ; 4(1): 75-81, 2000 Nov 09.
Article in English | MEDLINE | ID: mdl-11074016

ABSTRACT

A reporter construct was assembled with 4-kb of renin 5'-flanking sequence fused to humanized green fluorescent protein (GFP) cDNA. Transgenic mice carrying this construct were produced and assayed for GFP expression. In the adult, expression was detected in juxtaglomerular (JG) cells of the kidney and granular convoluted tubular cells of the submandibular gland. Furthermore, treatment of mice with captopril induced GFP expression in renal vascular smooth muscle cells. During embryogenesis, GFP expression was first detected at embryonic day E13 in the adrenal gland and Wolffian duct. Expression was also seen in the developing renal vasculature as early as E14 and remained detectable through birth. Renal GFP expression became restricted to JG cells in adults. Fetal adrenal and gonadal arteries also expressed GFP. In the placenta, GFP was observed in giant cell trophoblasts, consistent with reports of renin expression in chorionic cells of both humans and mice. We conclude that 4 kb of renin 5' flank is sufficient to direct multiple known renin expression patterns. Furthermore, the renin-GFP construct characterized here will provide a useful vital reporter for renin expression.


Subject(s)
Aging/genetics , Embryo, Mammalian/chemistry , Embryo, Mammalian/metabolism , Gene Expression Regulation , Luminescent Proteins/genetics , Renin/genetics , Transgenes , Animals , Female , Gene Transfer Techniques , Green Fluorescent Proteins , Humans , Kidney/blood supply , Kidney/chemistry , Kidney/metabolism , Luminescent Proteins/biosynthesis , Male , Mice , Mice, Transgenic , Placenta/chemistry , Placenta/metabolism , Pregnancy , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Renin/biosynthesis , Submandibular Gland/chemistry , Submandibular Gland/metabolism , Urogenital System/chemistry , Urogenital System/metabolism
18.
Am Fam Physician ; 62(9): 2067-72, 2000 Nov 01.
Article in English | MEDLINE | ID: mdl-11087188

ABSTRACT

Patients with acute brachial plexus neuritis are often misdiagnosed as having cervical radiculopathy. Acute brachial plexus neuritis is an uncommon disorder characterized by severe shoulder and upper arm pain followed by marked upper arm weakness. The temporal profile of pain preceding weakness is important in establishing a prompt diagnosis and differentiating acute brachial plexus neuritis from cervical radiculopathy. Magnetic resonance imaging of the shoulder and upper arm musculature may reveal denervation within days, allowing prompt diagnosis. Electromyography, conducted three to four weeks after the onset of symptoms, can localize the lesion and help confirm the diagnosis. Treatment includes analgesics and physical therapy, with resolution of symptoms usually occurring in three to four months. Patients with cervical radiculopathy present with simultaneous pain and neurologic deficits that fit a nerve root pattern. This differentiation is important to avoid unnecessary surgery for cervical spondylotic changes in a patient with a plexitis.


Subject(s)
Brachial Plexus Neuritis/complications , Brachial Plexus Neuritis/diagnosis , Shoulder Pain/etiology , Acute Disease , Aged , Analgesics/therapeutic use , Brachial Plexus Neuritis/therapy , Combined Modality Therapy , Diagnosis, Differential , Electromyography , Humans , Magnetic Resonance Imaging , Male , Muscle Weakness/etiology , Physical Therapy Modalities
19.
Pain ; 83(2): 137-45, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10534584

ABSTRACT

To understand the relative efficacy of noradrenergic and serotonergic antidepressants as analgesics in chronic back pain without depression, we conducted a randomized, double-blind, placebo-control head-to-head comparison of maprotiline (a norepinephrine reuptake blocker) and paroxetine (a serotonin reuptake blocker) in 103 patients with chronic low back pain. Of these 74 completed the trial; of the 29 who did not complete, 19 were withdrawn because of adverse effects. The intervention consisted of an 8-week course of maprotiline (up to 150 mg daily) or paroxetine (up to 30 mg daily) or an active placebo, diphenhydramine hydrochloride (up to 37.5 mg daily). Patients were excluded for current major depression. Reduction in pain intensity (Descriptor Differential Scale scores) was significantly greater for study completers randomized to maprotiline compared to placebo (P=0.023), and to paroxetine (P=0.013), with a reduction of pain by 45% compared to 27% on placebo and 26% on paroxetine. These results suggest that at standard dosages noradrenergic agents may provide more effective analgesia in back pain than do selective serotonergic reuptake inhibitors.


Subject(s)
Adrenergic Uptake Inhibitors/therapeutic use , Low Back Pain/drug therapy , Low Back Pain/physiopathology , Maprotiline/therapeutic use , Paroxetine/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adrenergic Uptake Inhibitors/adverse effects , Adult , Aged , Chronic Disease , Diphenhydramine/adverse effects , Diphenhydramine/therapeutic use , Double-Blind Method , Humans , Hypnotics and Sedatives/adverse effects , Hypnotics and Sedatives/therapeutic use , Maprotiline/adverse effects , Middle Aged , Pain Measurement , Paroxetine/adverse effects , Patient Selection , Placebos , Selective Serotonin Reuptake Inhibitors/adverse effects
20.
Pain ; 83(2): 369-77, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10534610

ABSTRACT

The primary purpose of this study was to examine the extent to which specific patient attitudes and beliefs about medical care and self-care for back pain predict future healthcare use. An automated database allowed examination of the predictive relationships in two primary care patient samples. In general, beliefs that physicians should find a definitive cause and permanent cure for back pain predicted neither physician visits nor prescription medication fills. Patient attitudes endorsing the benefits of medical treatment for back pain (as opposed to a permanent cure) predicted the use of these specific healthcare services. In a third sample of primary care back pain patients, we assessed whether a four-session self-care intervention modified those attitudes and beliefs shown to predict future healthcare use. The group intervention was associated with changes in attitudes about use of physician services but not medication use. A secondary purpose was to examine initial psychometric properties of a proposed back pain Self-Care Orientation Scale made up of the original 11 items. Factor analyses of the item set yielded three factors, but inconclusive results; the internal consistency of the identified sub-scales was only moderate. However, findings that a subset of items predicted physician visits and prescriptions medication fills, and was sensitive to change following a self-care intervention, suggest avenues for improving measurement of self-care orientation. These findings help clarify specific patient attitudes and beliefs that are related to healthcare utilization and suggest that a subset of these beliefs can be modified through a brief educational intervention.


Subject(s)
Attitude to Health , Back Pain/physiopathology , Back Pain/therapy , Patient Education as Topic , Self Care , Back Pain/rehabilitation , Chi-Square Distribution , Databases as Topic , Female , Health Maintenance Organizations , Humans , Interviews as Topic , Longitudinal Studies , Male , Middle Aged , Pain Measurement , Problem Solving , Registries , Surveys and Questionnaires , Washington , White People
SELECTION OF CITATIONS
SEARCH DETAIL
...